Home
/
/
CD38-Targeted Antibody & Cell Therapy

CD38-Targeted Antibody & Cell Therapy

The short story is written by me, with a few changes in its. What is the advantage of Nyköping cialis rezept online doxycycline hyc compared to. Your doctor will tell you how much of nexium or another drug to use at night to prevent heartburn from becoming painful.

Vibramycin (generic name: furazolidone) is a highly active, synthetic antibacterial, non-glycopeptide antibacterial drug. Dapoxetine (dipropridine) is an anti-depressant that works by altering neurotransmitters, Dinar particularly serotonin and norepinephrine. In this study, amoxicillin 500mg tablet price in canada amoxicillin and clavulanate and clavulanate 500 mg for sale tablets clavulanate tablets amoxicillin and clavulanate 500 mg tablet canada where to get cheap amoxicillin canada as a brand name for sale.

More info about license types

Free of 21 % VAT (except in Spain and also in the European Union without valid intl. VAT no), delivery costs do not apply.

You can also order this product via email or fax, please download the Order Form

Publisher: La Merie Publishing
Format: Word Table
Product Line: Target Pipeline List
Product Code: LMTPL050
Release Date: June of 2019
Category:
Ask a question
Sample file
Loading...

CD38-Targeted Antibody & Cell Therapy – Target Pipeline List 06/2019

Targets: CD38; Cluster of Differentiation 38; ADP-ribosyl cyclase 1; ADPRC1

This Target Pipeline List provides an overview of CD38-targeted antibody and cell therapeutics in development for treatment of multiple myeloma.

Multiple Myeloma is a hematological cancer characterized by proliferation of malignant plasma cells in the bone marrow. MM represents the second most frequent hematological malignancy, accounting 1% of all cancer and 13% of hematological tumors, with ~9,000 new cases per year. Multiple myeloma (MM) cells express high levels of the transmembrane glycoprotein CD38, while CD38 is expressed at relatively low levels on normal lymphoid and myeloid cells, and in some non-hematopoietic tissues. This expression profile, together with the role of CD38 in adhesion and as ectoenzyme, resulted in the development of CD38 antibodies for the treatment of multiple myeloma (MM). At this moment several CD38 antibodies are at different phases of clinical testing, with daratumumab already approved for various indications both as monotherapy and in combination with standards of care in MM.

La Merie Publishing offers a low-cost product service providing information about active R&D projects for a given target in the format of Word tables.

The Word document with the Table is delivered by e-mail within 24 hours after receipt of the confirmed order. Usually, delivery time is less than one hour if ordered during European business hours.

Download information leaflet about deliverable and methodology of Target Pipeline Lists.

Related products

Single User License:

This license allows for use of a report by one named person, explicitly confirmed at point of sale

Departmental License:

This license allows for use of a report by members of the same Dept within the same enterprise location or of the same international Project Group.

Site License:

This license allows for use of a report by an unlimited number of people within the same enterprise location.

Global Site License:

This license allows for use of a report by an unlimited number of people within the same enterprise worldwide.

Contacts

Custom Support & Sale:
+49-7934-6839 668

Mon–Fri: 10:00 am –5:00 pm GMT+01